We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.
- Authors
Navid, Fariba; Sondel, Paul M; Barfield, Raymond; Shulkin, Barry L; Kaufman, Robert A; Allay, Jim A; Gan, Jacek; Hutson, Paul; Seo, Songwon; Kim, Kyungmann; Goldberg, Jacob; Hank, Jacquelyn A; Billups, Catherine A; Wu, Jianrong; Furman, Wayne L; McGregor, Lisa M; Otto, Mario; Gillies, Stephen D; Handgretinger, Rupert; Santana, Victor M
- Abstract
The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with high-risk neuroblastoma. However, this therapy is limited by ch14.18-related toxicities that may be partially mediated by complement activation. We report the results of a phase I trial to determine the maximum-tolerated dose (MTD), safety profile, and pharmacokinetics of hu14.18K322A, a humanized anti-GD2 mAb with a single point mutation (K322A) that reduces complement-dependent lysis.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Vol 32, Issue 14, p1445
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2013.50.4423